Andersen YMF, Egeberg A, Ban L, Gran S, Williams HC, Francis NA, Knop FK, Gislason GH, Skov L, Thyssen JP. Association between topical corticosteroid use and type 2 ciabetes in two European population-based adultcCohorts. Diabetes Care 2019;42:junio. [Ref.ID 103163]

Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]

Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, Duckworth WC, Hayward RD, VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med 2019;380:6 de junio. [Ref.ID 103135]

Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium–glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med 2019:7 de mayo. [Ref.ID 103108]

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues A, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology 2019:6 de marzo. [Ref.ID 103052]

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]

Abrahami D, Douros A, Yin H, Hu OHY, Faillie J-L, Montastruc F, Platt RW, Bouganim N, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:5 de diciembre. [Ref.ID 102894]

Young K. Diabetes guidelines updated. Journal Watch 2018:1. [Ref.ID 102893]

Lipska KJ, Parker MM, Moffet HH, Huanq ES, Karter AJ. Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. JAMA 2018;320:3 de julio. [Ref.ID 102885]

Ueda P, Svanström H, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018;363:14 de noviembre. [Ref.ID 102869]

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2018:9 de noviembre. [Ref.ID 102850]

Nguyen TTH, Roussin A, Rousseau A, Montastruc J-L, Montastruc F. Role of serotonin transporter in antidepressant-induced diabetes mellitus: A pharmacoepidemiological–pharmacodynamic study in VigiBase®. Drug Saf 2018;41:noviembre. [Ref.ID 102840]

Samper E. Así influyen las farmacéuticas sobre los médicos . eldiario.es 2018:18 de octubre. [Ref.ID 102834]

Anónimo. FDA warns SGLT2 inhibitors can cause flesh-eating genitali infection. DIA Daily 2018:1. [Ref.ID 102830]

Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med 2018:13 de agosto. [Ref.ID 102824]

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 2018;362:k2693. [Ref.ID 102821]

Palmer SC, Strippoli GFM. Metformin as first-line treatment for type 2 diabetes . Lancet 2018;392:14 de julio. [Ref.ID 102743]

Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102675]

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]